These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 39401737)

  • 1. Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation.
    Pezeshkpoor B; Sereda N; Becker-Gotot J; Berkemeier AC; Matuschek I; Müller J; Ramaraje Urs SU; Singh S; Klein C; Marquardt N; Oldenburg J
    J Thromb Haemost; 2024 Oct; ():. PubMed ID: 39401737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
    Takeyama M; Nogami K; Matsumoto T; Noguchi-Sasaki M; Kitazawa T; Shima M
    J Thromb Haemost; 2020 Apr; 18(4):825-833. PubMed ID: 31984625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.
    Kaneda M; Kawasaki R; Matsumoto N; Abe H; Tashiro Y; Inokuchi Y; Yasuno H; Sasaki-Noguchi M; Soeda T; Yoshimura Y; Oka T
    J Thromb Haemost; 2021 Dec; 19(12):2938-2946. PubMed ID: 34418287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emicizumab for the treatment of acquired hemophilia A.
    Knoebl P; Thaler J; Jilma P; Quehenberger P; Gleixner K; Sperr WR
    Blood; 2021 Jan; 137(3):410-419. PubMed ID: 32766881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should emicizumab be used in patients with acquired hemophilia A?
    Tiede A; Kemkes-Matthes B; Knöbl P
    J Thromb Haemost; 2021 Mar; 19(3):637-644. PubMed ID: 33306259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: Case report of a first noninhibitor patient and review of the literature.
    Kizilocak H; Guerrera MF; Young G
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102194. PubMed ID: 37732158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group.
    Pfrepper C; Klamroth R; Oldenburg J; Holstein K; Eichler H; Hart C; Moehnle P; Schilling K; Trautmann-Grill K; Alrifai M; Ay C; Miesbach W; Knoebl P; Tiede A
    Hamostaseologie; 2023 Dec; ():. PubMed ID: 38049124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emicizumab as first-line therapy in acquired hemophilia A.
    Iarossi M; Hermans C
    Res Pract Thromb Haemost; 2024 May; 8(4):102438. PubMed ID: 38953052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acquired hemophilia A and emicizumab for the treatment of bleeding: two case report and a literature review].
    Launois A; Martin-Toutain I; Devaux F; Lambert J; Longval T; Merabet F; Jaidi R; Le Dore S; Ferre E; Rousselot P; De Raucourt E; Flaujac C
    Ann Biol Clin (Paris); 2024 Aug; 82(3):294-307. PubMed ID: 39150152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of emicizumab in acquired hemophilia A: A case report.
    Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP
    Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab.
    Bou-Jaoudeh M; Mimoun A; Delignat S; Peyron I; Capdevila L; Daventure V; Deligne C; Dimitrov JD; Christophe OD; Denis CV; Lenting PJ; Proulle V; Lacroix-Desmazes S
    J Thromb Haemost; 2023 Oct; 21(10):2776-2783. PubMed ID: 37473843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report.
    Al-Banaa K; Alhillan A; Hawa F; Mahmood R; Zaki A; El Abdallah M; Zimmerman J; Musa F
    Am J Case Rep; 2019 Jul; 20():1046-1048. PubMed ID: 31318850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor.
    Valsecchi C; Gobbi M; Beeg M; Adams T; Castaman G; Schiavone L; Huntington JA; Peyvandi F
    J Thromb Haemost; 2021 Mar; 19(3):711-718. PubMed ID: 33370499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low immunogenicity of emicizumab in persons with haemophilia A.
    Schmitt C; Emrich T; Chebon S; Fernandez E; Petry C; Yoneyama K; Kiialainen A; Howard M; Niggli M; Paz-Priel I; Chang T
    Haemophilia; 2021 Nov; 27(6):984-992. PubMed ID: 34480814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.
    Teranishi-Ikawa Y; Soeda T; Koga H; Yamaguchi K; Kato K; Esaki K; Asanuma K; Funaki M; Ichiki M; Ikuta Y; Ito S; Joyashiki E; Komatsu SI; Muto A; Nishimura K; Okuda M; Sanada H; Sato M; Shibahara N; Wakabayashi T; Yamaguchi K; Matsusaki A; Sampei Z; Shiraiwa H; Konishi H; Kawabe Y; Hattori K; Kitazawa T; Igawa T
    J Thromb Haemost; 2024 Feb; 22(2):430-440. PubMed ID: 37940048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding.
    Pasca S; Zanon E; Mannucci PM; Peyvandi F
    Blood Transfus; 2023 Nov; 21(6):549-556. PubMed ID: 36795341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel treatment strategies for acquired hemophilia A].
    Higasa S
    Rinsho Ketsueki; 2024; 65(6):560-566. PubMed ID: 38960657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of anti-factor VIII IgG ELISA in acquired hemophilia A follow-up.
    Chansavang A; Philippe A; Bozinovic I; Ben Hadj Ali K; Smadja D; Helley D; Darnige L; Mauge L
    Ann Hematol; 2022 Nov; 101(11):2453-2460. PubMed ID: 36125542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.